Literature DB >> 15356213

Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines.

Lazaros A Nikolaidis1, Aaron Doverspike, Teresa Hentosz, Lee Zourelias, You-Tang Shen, Dariush Elahi, Richard P Shannon.   

Abstract

We have recently demonstrated the benefits of glucagon-like peptide-1 (GLP-1) in enhancing regional and global myocardial function after reperfusion in the clinical setting of acute myocardial infarction. We hypothesized that GLP-1 facilitates recovery from myocardial stunning after an ischemic event. To investigate this, we administered GLP-1 (1.5 pmol/kg/min) to six dogs undergoing 10-min occlusion of the left circumflex coronary artery, followed by 24-h reperfusion. We compared the responses of coronary blood flow and regional thickening of the posterior wall with a group of eight vehicle-treated dogs undergoing the same occlusion-reperfusion protocol. Although recovery of coronary blood flow was identical, regional wall motion recovery occurred significantly ((*)p < 0.05) earlier (92 +/- 4 versus 57 +/- 5%(*) at 15 min) and was complete in the GLP-1-treated dogs, whereas residual contractile dysfunction persisted in the control group (99 +/- 4 versus 78 +/- 3%(*) at 24 h). This phenomenon was independent of changes in systemic hemodynamics or global systolic function. However, isovolumic left ventricular relaxation improved significantly in GLP-1-treated dogs. GLP-1 caused an insulinotropic effect, but no hypoglycemia. We conclude that GLP-1 enhances recovery from ischemic myocardial stunning after successful reperfusion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356213     DOI: 10.1124/jpet.104.073890

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  42 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.

Authors:  Cyrus DeSouza; Vivian Fonseca
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

Review 3.  Glucagon-like peptide-1 and its cardiovascular effects.

Authors:  Kyung-Sun Heo; Keigi Fujiwara; Jun-ichi Abe
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

Review 4.  Incretin-related drug therapy in heart failure.

Authors:  Amanda R Vest
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 5.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

6.  Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.

Authors:  Wei-Ren Chen; Xue-Qin Shen; Ying Zhang; Yun-Dai Chen; Shun-Ying Hu; Geng Qian; Jing Wang; Jun-Jie Yang; Zhi-Feng Wang; Feng Tian
Journal:  Endocrine       Date:  2015-11-16       Impact factor: 3.633

Review 7.  The evolving place of incretin-based therapies in type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Pediatr Nephrol       Date:  2010-02-04       Impact factor: 3.714

8.  GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Authors:  Mohammad Hossein Noyan-Ashraf; M Abdul Momen; Kiwon Ban; Al-Muktafi Sadi; Yu-Qing Zhou; Ali M Riazi; Laurie L Baggio; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2009-01-16       Impact factor: 9.461

9.  Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.

Authors:  Jens Kristensen; Ulrik M Mortensen; Morten Schmidt; Peter Haubjerg Nielsen; Torsten Toftegaard Nielsen; Michael Maeng
Journal:  BMC Cardiovasc Disord       Date:  2009-07-23       Impact factor: 2.298

10.  Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.

Authors:  Anne Gill; Byron J Hoogwerf; Jude Burger; Simon Bruce; Leigh Macconell; Ping Yan; Daniel Braun; Joseph Giaconia; James Malone
Journal:  Cardiovasc Diabetol       Date:  2010-01-28       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.